Abstract:Glutamine, like glucose, is a major nutrient consumed by cancer cells, yet these cells undergo glutamine starvation in the cores of tumors, forcing them to evolve adaptive metabolic responses. Pharmacologically targeting glutamine metabolism or withdrawal has been exploited for therapeutic purposes, but does not always induce cancer cell death. The mechanism by which cancer cells adapt to resist glutamine starvation in cisplatin-resistant non-small-cell lung cancer (NSCLC) also remains uncertain. Here, we report the potential metabolic vulnerabilities of A549/DDP (drug-resistant human lung adenocarcinoma cell lines) cells, which were more easily killed by the iron chelator deferoxamine (DFO) during glutamine deprivation than their parental cisplatin-sensitive A549 cells. We demonstrate that phenotype resistance to cisplatin is accompanied by adaptive responses during glutamine deprivation partly via higher levels of autophagic activity and apoptosis resistance characteristics. Moreover, this adaptation could be explained by sustained glucose instead of glutamine-dominant complex II-dependent oxidative phosphorylation (OXPHOS). Further investigation revealed that cisplatin-resistant cells sustain OXPHOS partly via iron metabolism reprogramming during glutamine deprivation. This reprogramming might be responsible for mitochondrial iron-sulfur [Fe-S] cluster biogenesis, which has become an “Achilles’ heel,” rendering cancer cells vulnerable to DFO-induced autophagic cell death and apoptosis through c-Jun N-terminal kinase (JNK) signaling. Finally, in vivo studies using xenograft mouse models also confirmed the growth-slowing effect of DFO. In summary, we have elucidated the adaptive responses of cisplatin-resistant NSCLC cells, which balanced stability and plasticity to overcome metabolic reprogramming and permitted them to survive under stress induced by chemotherapy or glutamine starvation. In addition, for the first time, we show that suppressing the growth of cisplatin-resistant NSCLC cells via iron chelator-induced autophagic cell death and apoptosis was possible with DFO treatment. These findings provide a solid basis for targeting mitochondria iron metabolism in cisplatin-resistant NSCLC for therapeutic purposes, and it is plausible to consider that DFO facilitates in the improvement of treatment responses in cisplatin-resistant NSCLC patients.

Iron chelation inhibits cancer cell growth and modulates global histone methylation status in colorectal cancer

Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism

An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells

Iron Regulates the Warburg Effect and Ferroptosis in Colorectal Cancer

The Role of Iron Chelation in Cancer Therapy

Flavonoid 4,4′-Dimethoxychalcone Induced Ferroptosis in Cancer Cells by Synergistically Activating Keap1/Nrf2/HMOX1 Pathway and Inhibiting FECH

Defetoxamine (DFO) induces the demethylation of P15INK4B gene in myelodysplastic syndrome (MDS) cell line SKM-1

Iron Overloading Potentiates the Antitumor Activity of 5-Fluorouracil by Promoting Apoptosis and Ferroptosis in Colorectal Cancer Cells

Reversing oncogenic transformation with iron chelation

Deferoxamine Suppresses Esophageal Squamous Cell Carcinoma Cell Growth Via ERK1/2 Mediated Mitochondrial Dysfunction

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine

A DFX-based iron nanochelator for cancer therapy

Iron metabolism in colorectal cancer: a balancing act

Targeting Ferroptosis in Colorectal Cancer

Deferoxamine alleviates chondrocyte senescence and osteoarthritis progression by maintaining iron homeostasis

Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy

Deferoxamine Counteracts Cisplatin Resistance in A549 Lung Adenocarcinoma Cells by Increasing Vulnerability to Glutamine Deprivation-Induced Cell Death

Ferritin Is A Potential Tumor Marker For Colorectal Cancer And Modulates Histone Methylation In Colorectal Cancer Cells

Novel meroterpene-like compounds inhibit ferroptosis through Fe2+ chelation

The iron chelator deferriferrichrysin induces paraptosis via extracellular signal-related kinase activation in cancer cells

Iron promotes ovarian cancer malignancy and advances platinum resistance by enhancing DNA repair via FTH1/FTL/POLQ/RAD51 axis